Cisplatin + etoposide (EP)
Checked 2026-09-09
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
One cycle
every 21 days × 4 · about 12 weeks in totalComponents
Cycles
4
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine
Notes
- ADRIATIC: durvalumab consolidation for up to 2 years after chemoradiation in limited-stage disease.
- G-CSF is generally avoided during concurrent thoracic radiotherapy.
Used in
Source
NCCN Small Cell Lung Cancer; CONVERT, Lancet Oncology 2017
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
CAPTEM
Advanced pancreatic neuroendocrine tumour
every 28 days
177Lu-DOTATATE (PRRT)
SSTR-positive gastroenteropancreatic NET after somatostatin analogue
every 56 days × 4
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Pembrolizumab + pemetrexed + platinum
Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1
every 21 days × 4
Pembrolizumab + carboplatin + paclitaxel
Metastatic squamous NSCLC, first line
every 21 days × 4
Nivolumab + ipilimumab + 2 cycles of platinum doublet
Metastatic NSCLC without EGFR/ALK alteration, first line
every 21 days
Osimertinib
EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)
every 28 days